Do you want to read an article? Please log in or register.
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Lancet Respir Med.
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC
Lung Cancer
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
Eur J Cancer.
Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B
doi: 10.1016/j.ejca.
RECOMMENDED
Lung CancerPleural DiseasesFurther Publications
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
Chest.
Suresh K, Naidoo J, Lin CT, Danoff S
doi: 10.1016/
RECOMMENDED
Lung Cancer
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug
Lung Cancer.
Stahel RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes KL, Kohler M, Guckenberger M, Weder W
doi: 10.1016/j.lungcan.2020.05.037.
RECOMMENDED
Lung Cancer
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
Lung Cancer.
Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A
doi: 10.1016/j.lungcan.2020.04.027.
RECOMMENDED
Lung Cancer
Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer.
Stinchcombe TE, Miksad RA, Gossai A, Griffith SD, Torres AZ
doi: 10.1016/j.cllc.2020.04.008.
RECOMMENDED
Lung Cancer
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Sun L, Davis CW, Hwang WT, Jeffries S, Sulyok LF, Marmarelis ME, Singh AP, Berman AT, Feigenberg SJ, Levin W, Ciunci CA, Bauml JM, Cohen RB, Langer CJ, Aggarwal C
doi: 10.1016/j.cllc.2020.10.017
RECOMMENDED
Lung Cancer
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P
doi: 10.1016/j.cllc.2021.03.006
RECOMMENDED
Lung Cancer
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A
doi: 10.1016/j.cllc.2021.06.013